Talzenna
Named-patient access overview. Talzenna is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Talzenna (talazoparib) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor approved by the US Food and Drug Administration in October 2018 for deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer, with subsequent FDA approval in June 2023 in combination with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer. The product is marketed approximately by Pfizer.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Talzenna
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Talzenna is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Talzenna in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Talzenna
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.